Kornimate/medical-research-clean huggingface dataset:
effects of dark chocolate on exercise capacity, and mitochondrial structure and function

Conditions: Heart Failure; Type 2 Diabetes

Summary: the major goal of this study is to characterize the ability of dark chocolate enriched in epicatechin (a component of dark chocolate) to improve the structural and functional features of mitochondria in two groups 1. patients with heart failure (hf) and type 2 diabetes (dm2) and 2. normal yet sedentary individuals with impaired baseline exercise capacity (as assessed by vo2 max) we propose that a 3 month treatment with dark chocolate will lead to a significant improvement in exercise capacity which will be secondary to the improvement in skeletal muscle structure from epicatechin.

the flavanol epicatechin (which is derived from cocoa and has no known toxicity in humans) has been shown in clinical trials to increase levels of nitric oxide (no) as assessed by flow-mediated dilation (fmd) in the brachial artery and measurements of circulating no in plasma. no is thought to be an activator of pgc-1 alpha \[ppar (peroxisome proliferator-activated receptor) alpha coactivator 1\] which stimulates mitochondrial biogenesis. in both patients with heart failure and diabetes there is nitric oxide deficiency and mitochondrial dysfunction. in our proposed double-blinded placebo controlled clinical trial, we will test the hypothesis that chronic administration of epicatechin to patients with both heart failure and diabetes will increase levels of no and pgc-1 alpha leading to increased mitochondrial biogenesis and improved mitochondrial function. we believe similar changes will occur in sedentary individuals. in a preliminary study with 5 patients with heart failure and diabetes (conducted under ucsd irb protocol number #090688) we have shown that epicatechin enriched dark chocolate improves mitochondrial structure (taub pr, ramirez-sanchez i, ciaraldi tp, et al. alterations in skeletal muscle indicators of mitochondrial structure and biogenesis in patients with type 2 diabetes and heart failure: effects of epicatechin rich cocoa. clin transl sci. 2011;5(1):43-47.)

Eligibility criteria:
healthy, sedentary individuals: inclusion criteria: * healthy, inactive individuals * bmi 27-32 exclusion criteria: * smoking or quit smoking less than 1 year prior to enrollment * currently taking coumadin or pradaxa. heart failure and diabetes patients: inclusion criteria: * medically diagnosed with heart failure and diabetes * no significant hba1c fluctuations in past 6 months exclusion criteria: * currently taking insulin * currently taking coumadin or pradaxa. * smoking or quit smoking less than 1 year prior to enrollment

Keywords: mitochondrial biogenesis skeletal muscle epicatechin
iv paracetamol versus iv dexketoprofen in dysmenorrhea

Conditions: Dysmenorrhea

Summary: patients presented with dysmenorrhea composed the study population. one gram paracetamol and 50 mg dexketoprofen in 100 ml saline with a rapid infusion were compared in ceasing dysmenorrhea in emergency department.

patients over 18 years old who presented with dysmenorrhea composed the study population. patients received pain killer within the last six hours, physical findings consistent with peritoneal irritation, allergy to the study drugs, renal or liver failure, drug addiction, pregnancy or woman with lactation and denied to give inform consent were the exclusion criteria. the pain of the study patients are measured with visual analogue scale at baseline, 15th and 30th minutes. at the end of the 30 minutes, rescue drug need is also recorded.

Eligibility criteria:
inclusion criteria: * patients with dysmenorrhea * patients over 18 years old exclusion criteria: * denied to give inform consent * renal or liver failure * allergy to the study drugs * receiving pain killer within the last 6 hours. * physical examination findings consistent with peritoneal irritation * pregnancy or patients with lactation * drug addiction
palatal donor site wound healing following periodontal plastic surgery using amnion-chorion membrane

Conditions: Palate; Wound

Summary: the purpose of this clinical trial is to assess if donor site healing in the palatal area and patient pain perception are similar or different when using amnio-chorion membrane (acm) on the donor site after surgery compared to a commonly used commercial hemostatic agent (actcel cellulose gauze).

resorbable oxidized cellulose materials are commonly used as hemostatic agents in medicine and dentistry. surgicel and actcel are used daily in surgical practice. when these products come in contact with blood, they convert to a gel that expands to cause direct pressure on blood vessels and control bleeding. actcel is water-soluble and dissolves over a short time period. it can be removed easily when water, saline or hydrogen peroxide is applied.the study team will examine the effects of acm as a wound dressing for the donor area and compare the rate of epithelialization with and without its use.

Eligibility criteria:
inclusion criteria: * patients between age 18 and 89 * patients needing an fsta in the area of the mouth from 2nd molar to 2nd molar in the maxilla or mandible at sites that have teeth or implants, or in sites that are edentulous * patients must be nonsmokers, former smokers, or current smokers who smoke \<10 cigarettes per day, by self-report * female patients who have undergone a hysterectomy, tubal ligation, or menopause, and non- pregnant women of child-bearing potential. * must have access to smartphone exclusion criteria: * patients who disclose that they will not be able to cooperate with the follow-up schedule. * patients who are mentally incompetent, prisoners, or pregnant (as obtained via chart review or self-report) * pregnant women or women intending to become pregnant during study period * smokers who smoke \> 10 cigarettes per day

Keywords: hemostatic agent amnion-chorion membrane accelerated wound healing periodontal plastic surgery
metabolic effects of subchronic dopamine d2 receptor blockade by haloperidol in healthy humans

Conditions: Insulin Resistance; Dyslipidemia

Summary: we hypothesized that short-term treatment with haloperidol induces insulin resistance through a mechanistic route that is independent of weight gain. we therefore treated healthy non-obese men with haloperidol for 8 days, and studied the impact of these intervention on glucose and lipid metabolism by hyperinsulinemic euglycemic clamp, isotope dilution technology and indirect calorimetry.


Eligibility criteria:
inclusion criteria: * healthy men * 20 kg/m2 \< bmi \< 26 kg/m2 * age 20-40 years * fpg \< 6 mmol/l exclusion criteria: * fpg \> 6 mmol/l * bmi \> 26 kg/m2 * psychiatric disorders and/or use of antipsychotic or antidepressants drugs at present or in the past. * a positive family history of schizophrenia * any significant chronic disease * renal, hepatic or endocrine disease * use of medication known to influence lipolysis and/or glucose metabolism * total cholesterol \> 7mmol/l and/or triglycerides \> 2 mmol/l * recent weight changes or attempts to loose weight (\> 3 kg weight gain or loss, within the last 3 months) * difficulties to insert an intravenous catheter * smoking (current) * severe claustrophobia (ventilated hood) * recent blood donation (within the last 2 months) * recent participation in other research projects (within the last 3 months), participation in 2 or more projects in one year * extensive sporting activities (more than 10 hours of exercise per week)

Keywords: insulin resistance dyslipidemia haloperidol
characterizing adherence to treatment and satisfaction with care in patients with cutaneous lupus

Conditions: Cutaneous Lupus

Summary: this multicenter study aims to evaluate treatment adherence and satisfaction of patients with cutaneous lupus, influenced by perception of the disease, fear of side effects, cost of medications and the doctor-patient relationship. adherence will be measured by a vas of 80% or higher on the medical adherence self-report inventory scale.

this multicenter, cross-sectional study aims to characterize adherence to treatment and satisfaction of patients with cutaneous lupus. non-adherence to treatment is a major problem, influenced by perception of the disease, fear of adverse effects, cost of medications and the doctor-patient relationship. adherence will be measured by a vas of 80% or more on the visual analog scale of the medical adherence self-report inventory questionnaire. the study is descriptive, multicenter and cross-sectional. participants will be adult patients suffering from cutaneous lupus, diagnosed by a dermatologist and under treatment, able to complete questionnaires. patients with systemic lupus, cognitive or psychiatric disorders will be excluded from the study. the inclusion period is two years, with 30 minutes of follow-up per participant. the study will provide a better understanding of the feelings of patients with cutaneous lupus and the factors limiting their adherence to treatment.

Eligibility criteria:
inclusion criteria: * patients with cutaneous lupus (pure cutaneous or subacute) diagnosed by a dermatologist and under local and/or systemic treatment for cutaneous lupus * no opposition to participation * patient able to complete the questionnaires * adult patient exclusion criteria: * systemic lupus with multiple visceral involvement * cognitive or psychiatric disorders preventing the smooth running of the study * pregnant woman * patient under guardianship/curatorship or safeguard of justice
prevention of delirium in inpatients utilizing melatonin

Conditions: Delirium

Summary: a double blind randomized controlled trial investigating melatonin, 5mg, compared to placebo, given to patients at least 65 years old, admitted to the hospital on a general medical floor, to prevent delirium.

this study will be a randomized double blind controlled trial, designed to evaluate the efficacy of melatonin in decreasing the incidence of delirium in elderly hospitalized adults compared to a placebo capsule. the study will be conducted on 4 general internal medicine inpatient floors at yale-new haven hospital, st. raphael's campus. within 24 hours of admission to the floor, study subjects will be approached by a member of the research team, and asked for informed consent. patients that consent to participate will be randomized to either the treatment or the placebo arm. each subject will be administered a capsule containing either placebo or 5 mg melatonin each evening at 9 p.m. the capsules will be prepared and administered by the yale-new haven hospital investigational drug service. the capsules will be administered nightly until discharge or a maximum of 2 weeks, if the hospitalization is prolonged. subjects will be assessed twice daily by the floor nurses for evidence of delirium using the short cam (confusion assessment method), which is a validated clinical tool for identifying delirium, and the current standard of practice tool for the diagnosis of delirium.

Eligibility criteria:
inclusion criteria: * inpatient admission to a general internal medicine service exclusion criteria: * expected lifespan or length of stay ≤ 48 hours * non-english speaking * already taking melatonin or ramelteon at the time of randomization * presence of delirium at the time of randomization * unable to take oral medications * subject or proxy unable to provide informed consent within 18 hours of invitation or 24 hours of admission * alt or ast (liver function tests) \> 3 times the upper limit of normal * taking warfarin, nifedipine or fluvoxamine * allergy to melatonin * unable to recall 3 words after distraction by naming the days of the week backwards beginning with sunday

Keywords: prevention; delirium; in-patients; melatonin,
phase iii randomized, double-blind, placebo-controlled study of copolymer 1 for relapsing-remitting multiple sclerosis

Conditions: Multiple Sclerosis

Summary: objectives: i. compare tolerance to and therapeutic impact of copolymer 1, a mixture of synthetic polypeptides, with placebo in patients with relapsing-remitting multiple sclerosis.

protocol outline: this is a randomized, double-blind study. patients are stratified by participating institution. one group receives copolymer 1, a mixture of synthetic polypeptides composed of 4 amino acids, subcutaneously each day for 2 years. the other group receives an injection of placebo daily for 2 years.

Eligibility criteria:
protocol entry criteria: --disease characteristics-- * clinically or laboratory-supported definite multiple sclerosis * neurologically stable for at least 30 days prior to entry expanded disability status scale score no greater than 5 * at least 2 documented relapses within 2 years prior to entry onset of first relapse at least 1 year prior to randomization --prior/concurrent therapy-- * biologic therapy: no prior copolymer 1 * immunosuppressive therapy: no prior cytotoxic immunosuppressives, i.e.: azathioprine cyclophosphamide cyclosporine at least 30 days since corticosteroids * radiotherapy: no prior lymphoid irradiation --patient characteristics-- * not hiv or htlv-i seropositive no insulin-dependent diabetes mellitus no lyme disease no requirement for aspirin or chronic nonsteroidal anti-inflammatory drugs no pregnant or nursing women adequate contraception required of fertile women

Keywords: multiple sclerosis neurologic and psychiatric disorders rare disease
effect of inhaled aromatherapy on chemo-induced nausea vomiting (ncvi): cinvarom (chemotherapy induced nausea vomiting and aromatherapy)

Conditions: Nausea and Vomiting; Aromatherapy; Essential Oil; Suportive Care

Summary: the investigator wish to provide a blend of two essential oils with comparable antiemetic properties; peppermint essential oil (mentha x piperita) and lemon tree essential oil (citrus limon). dry inhalation of these essential oils is safe, but effectiveness has not been determined. studies on the subject present a questionable methodology. this is why we are proposing this study to measure the effectiveness of this mixture of essential oils on chemo-induced nausea and vomiting. this study is a first step before a possible study to compare the effects of essential oils with those of a placebo.


Eligibility criteria:
inclusion criteria: patients will be eligible if: * aged over 18, * presenting a solid tumor in the 1st line of chemotherapy administered by intravenous route; * treated with adjuvant or neoadjuvant chemotherapy; * affiliated with a social security scheme; * able to understand the meaning of the questions asked; * having given their written consent to participate in the study; * whether or not treated with surgery and radiotherapy before entering the study exclusion criteria: patients who: * do not give their consent to participate; * do not master the french language; * are deprived of their liberty, under guardianship or curatorship; * suffer from cognitive deficits or associated psychiatric disorders that could compromise their ability to participate in the study (eg: schizophrenia); * are undergoing radiotherapy; * must receive a combination of radio-chemotherapy; * whose chemotherapy protocol is composed of several chemotherapy administrations per week during a course of treatment; * have been previously treated with chemotherapy; * have an occlusive syndrome; * have primary cancer of the central nervous system or brain metastases; * have cancer of the upper aero digestive tract; * simultaneously participate in a therapeutic clinical trial; * have an intolerance to a component of essential oils; * pregnant or breastfeeding.
call to door timing in out-of-hospital cardiac arrest

Conditions: Cardiac Arrest; Morality

Summary: the investigators aimed to investigate the effect of delayed hospitalization on the basis of the call time on the clinical outcomes of patients with ohca patients using a nationwide ohca registry.

according to "2020 american heart association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care", immediate call for the local emergency response number takes a key role in the ohca as the cpr in community does not provide quality of in-hospital cpr. the strong recommendation of speedy transportation, however, does not provide time limitation, and evident data supporting benefit within certain minutes to transfer is lack through our best of search. therefore, the investigators aimed to investigate the effect of delayed hospitalization on the basis of the call time on the clinical outcomes of patients with ohca patients using a nationwide ohca registry.

Eligibility criteria:
inclusion criteria: * out-of-hospital cardiac arrest event exclusion criteria: * arrest of non-cardiac origin * age \< 18 years * no any cpr * missing data on call time

Keywords: cardiac arrest mortality timing
a couples-based approach for increasing physical activity among adults with type 2 diabetes

Conditions: Collaborative Implementation Intentions; Individual Implementation Intentions; Information Only Control Condition

Summary: in a 6-week experimental design, up to 90 adult couples in which one partner has type 2 diabetes (t2d) will be randomly assigned to either the collaborative implementation intentions (collaborative iis), the individual implementation intentions (individual iis) condition, or the control condition. as this is a pilot study, randomization for the experimental groups vs the control groups will occur at a 2:1 ratio. thus, the experimental conditions will contain up to 36 participants and the control condition will contain up to 18 participants. adults with t2d who are living with a romantic partner, not meeting current physical activity guidelines but able and willing to begin a new physical activity (pa) routine and their partners will be assessed at baseline, 3 weeks and 6 weeks after the experimental manipulation. partners will report on their own investment in the patient's goal and patients will report on their own pa self-efficacy. patient's pa will be measured through self-report, partner report and accelerometers for a week prior to each survey assessment. these specific aims are planned: aim 1: determine whether collaborative iis for patient's pa lead to a greater increase in partner investment in partners of adults with t2d than do individual iis or control. aim 2: determine whether collaborative iis for patient's pa lead to a greater increase in patient pa self-efficacy in adults with t2d than do individual iis or control. aim 3: determine whether collaborative iis for patient's pa lead to a greater increase in patient pa in adults with t2d than do individual iis or control.


Eligibility criteria:
inclusion criteria: * at least 21 years of age * able to read and understand english * does not meet physical activity guidelines (\< 150 minutes of moderate-vigorous exercise per week) for the last 3 months\* (only required of one partner) * diagnosed with type 2 diabetes\* (only required of one partner) * married or living with a romantic partner exclusion criteria: * medical or physical contraindications to participate in physical activity
diffusion tensor imaging in predicting development of chemotherapy induced peripheral neuropathy in patients with breast cancer (cipn)

Conditions: Breast Carcinoma; Breast Cancer; Neuropathy;Peripheral; Neuropathy

Summary: this pilot early phase i trial studies how well diffusion tensor imaging works in predicting development of chemotherapy induced peripheral neuropathy in patients with breast cancer. diffusion tensor imaging may help to get better pictures of the nerves of feet and lower legs before and after chemotherapy treatment and may help to predict the risk of developing peripheral neuropathy.

primary objectives: i. to assess the changes in the fractional anisotropy (fa) and apparent diffusion coefficient (adc) values of the lower extremity nerves by diffusion tensor imaging (dti) before initiation and after completion of taxane chemotherapy in patients with breast cancer. secondary objectives: i. establish normal and abnormal fa and adc values of the lower extremity nerves. ii. evaluate relationship of dti findings of chemotherapy induced peripheral neuropathy (cipn) with self-reported patient neurotoxicity questionnaire (pnq) and functional assessment of cancer therapy/gynecologic oncology group-neurotoxicity questionnaire (fact-got-ntx) questionnaires. iii. assess inter-reader variability in measuring fa and adc values. outline: patients undergo non-enhanced magnetic resonance imaging (mri) of both lower extremities using magnetic resonance neurography (mrn) and dti prior to initiation and after completion of standard of care chemotherapy.

Eligibility criteria:
inclusion criteria: * be capable of understanding the investigational nature of the study and all pertinent aspects of the study * be capable of signing and providing written consent in accordance with institutional and federal guidelines * have a histologically-confirmed diagnosis of breast cancer * need to be treated with taxane containing chemotherapy as determined by their treating physician * be able to undergo magnetic resonance (mr) imaging * be willing and able to comply with scheduled visits, treatment plan, and mr imaging exclusion criteria: * have non-mri compatible metallic objects on/in body * have metallic hardware in the lower extremity which is mr compatible however would create too much artifact for mr examination * are unable to lay still in the mr scanner for length of examination * have severe claustrophobia * have pre-existing peripheral neuropathy from other medical conditions or due to cancer * have diagnosis of diabetes * pregnant patients * prior exposure to neurotoxic chemotherapy

Keywords: diffusion tensor imaging chemotherapy peripheral neuropathy breast cancer mri magnetic resonance imaging diffusion tensor imaging
the effect of relaxation program on coping with stress and anxiety levels of caregivers of children with cancer.

Conditions: Caregivers With a Child Followed up With a Cancer Diagnosis

Summary: this research will be carried out to determine the effect of the relaxation program applied to the caregivers of children followed by the diagnosis of cancer on the levels of caregivers' anxiety and coping with stress. the research will be conducted in a single-blind parallel-group randomized controlled trial design. a relaxation program including progressive muscle relaxation exercises will be applied to caregivers. the application will be carried out by sending muscle relaxation videos and videos for relaxation to mothers. the relaxation program is planned to last approximately 6 weeks

in this study, a relaxation program will be applied to mothers who have a child followed up with a cancer diagnosis. the relaxation program will include progressive muscle relaxation exercises and videos for relaxation. initial applications will be implemented with caregivers. the relaxation program is planned to last 6 weeks. the program is planned to last 8 weeks in total, with pre-test and post-test applications. caregivers will then be asked to perform the treatments each week. coping with stress and state-trait anxiety scale will be used at the beginning and end of the program.

Eligibility criteria:
inclusion criteria * the child has received cancer treatment for at least two months, * those who have internet access on their smartphone or computer * those who can continue the work for six weeks (doing progressive relaxation exercises at least 2 times a week) exclusion criteria: * those whose children/caregivers are in the terminal period, * those whose child/caregiver has not received chemotherapy treatment, * those who take medication for anxiety or use one of the complementary medicine approaches.
post-marketing surveillance of dc bead in patients with hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: this surveillance's objectives are: 1. unknown adverse reactions 2. incidences of adverse drug reaction 3. factors considered to have effect to safety and effectiveness


Eligibility criteria:
inclusion criteria: patients with hepatocellular carcinoma exclusion criteria: none

Keywords: hepatocellular carcinoma